- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- MEDI7510, IIV
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 363 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Orlando, Florida • South Miami, Florida • Kansas City, Missouri + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 260
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Motavizumab, Placebo
- Biological · Other
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 0 Months to 6 Months
- Enrollment
- 2,127 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2010
- U.S. locations
- 12
- States / cities
- Chinle, Arizona • Cibecue, Arizona • Fort Definace, Arizona + 9 more
- Conditions
- RSV Immunization
- Interventions
- RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 6 Months to 12 Months
- Enrollment
- 2,226 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
- Conditions
- Respiratory Syncytial Viruses, Respiratory Tract Infections
- Interventions
- Ad26.RSV.preF (1*10^11 vp), Ad26.RSV.preF (5*10^10 vp), Placebo
- Biological · Drug
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 12 Months to 50 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Newton, Kansas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- AZM Group, Control Group
- Drug · Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 3 Days to 2 Years
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 12 more
- Conditions
- Influenza A, Influenza Type B, SARS CoV 2 Infection, RSV Infection
- Interventions
- Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections
- Diagnostic Test
- Lead sponsor
- Baebies, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,500 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Raleigh, North Carolina
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV vaccine
- Biological
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Respiratory Syncytial Virus Prevention
- Interventions
- Ad26.RSV.preF-based vaccine
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years to 75 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- San Diego, California • Lakeland, Florida • Melbourne, Florida + 4 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- Placebo, mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 3,317 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 62
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Garden Grove, California + 51 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV LID cp ΔM2-2 Vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA investigational vaccine, PCV20
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,113 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Guntersville, Alabama • Phoenix, Arizona • Huntington Beach, California + 17 more
- Conditions
- Influenza, Human, COVID-19, Influenza A, Influenza B, Respiratory Syncytial Virus (RSV)
- Interventions
- Not listed
- Lead sponsor
- Evidation Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,157 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- San Mateo, California
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSV ΔNS2/Δ1313/I1314L, RSV 276, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 24 Months
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 12
- States / cities
- La Jolla, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- RSV Infection, Drug Drug Interaction (DDI)
- Interventions
- EDP-323, Itraconazole, carbamazepine, Quinidine, fluconazole
- Drug
- Lead sponsor
- Enanta Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hematological Malignancies
- Interventions
- Ribavirin
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- QIAGEN ResPlex II Advanced Panel, Influenza A, Respiratory Syncytial Virus Infections, Infection Due to Human Parainfluenza Virus 1, Parainfluenza Type 2, Parainfluenza Type 3, Parainfluenza Type 4, Human Metapneumovirus A/B, Rhinovirus, Coxsackie Virus/Echovirus, Adenovirus Types B/C/E, Coronavirus Subtypes 229E, Coronavirus Subtype NL63, Coronavirus Subtype OC43, Coronavirus Subtype HKU1, Human Bocavirus, Artus Influenza A/B RT-PCR Test, Influenza B
- Interventions
- artus Influenza A/B RT-PCR Test
- Device
- Lead sponsor
- QIAGEN Gaithersburg, Inc
- Industry
- Eligibility
- Not listed
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 5
- States / cities
- Tuscon, Arizona • Albany, New York • Chapel Hill, North Carolina + 1 more
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Not listed
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- Up to 24 Months
- Enrollment
- 91 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Respiratory Syncytial Viruses
- Interventions
- Lumicitabine, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 28 Days to 36 Months
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 6
- States / cities
- Long Beach, California • Kansas City, Missouri • Syracuse, New York + 3 more
- Conditions
- Adult, Healthy Participants
- Interventions
- RSVpreF, Placebo
- Biological · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 14
- States / cities
- Scottsdale, Arizona • Lake Forest, California • Riverside, California + 11 more
- Conditions
- Respiratory Syncytial Virus Infections, Parainfluenza Infections
- Interventions
- MEDI-534
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Pittsburgh, Pennsylvania • Dallas, Texas
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- RSVPreF3 OA vaccine
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 10,212 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2026
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 50 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Saline Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,599 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
- Conditions
- Respiratory Syncytial Virus
- Interventions
- VRC-RSVRGP084-00-VP, Aluminum Hydroxide Suspension
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Respiratory Syncytial Virus, Bronchiolitis
- Interventions
- Oral azithromycin, Placebo
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 1 Month to 18 Months
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri